Ovid Therapeutics (OVID) Cash from Operations Growth (5y) (2021 - 2026)

Ovid Therapeutics (OVID) Cash from Operations Growth (5y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ovid Therapeutics 118.66 Mn -36.86 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -15.85%
Dec 31, 2025 6.49%
Sep 30, 2025 -54.24%
Jun 30, 2025 22.46%
Mar 31, 2025 11.00%
Dec 31, 2024 9.94%
Sep 30, 2024 -9.59%
Jun 30, 2024 -3.78%
Mar 31, 2024 -5.34%
Dec 31, 2023 -1.67%
Sep 30, 2023 -0.01%
Jun 30, 2023 -0.15%
Mar 31, 2023 1.29%
Dec 31, 2022 -0.37%
Sep 30, 2022 -6.34%
Jun 30, 2022 -17.29%
Mar 31, 2022 -22.93%
Dec 31, 2021 -16.00%
Sep 30, 2021 -18.59%
Jun 30, 2021 -40.01%